<DOC>
	<DOCNO>NCT01884558</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose isavuconazole pharmacokinetics single dose metformin . Safety tolerability isavuconazole assess alone combination metformin .</brief_summary>
	<brief_title>A Study Evaluate Effect Multiple Doses Isavuconazole Pharmacokinetics Metformin</brief_title>
	<detailed_description>Subjects check-in clinic Day -1 remain confined completion study procedure Day 10 . A follow-up telephone call make Day 16 check health status .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>The subject body weight least 45 kg body mass index 18 32 kg/m2 , inclusive . QTcF must 360 430 msec male 370 450 msec female Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) serum creatinine must normal range . Female subject nonchildbearing potential childbearing potential must use highly effective birth control Screening 28 day end study . Females must breastfeed donate ova Screening 20 day end study . Male subject must use highly effective contraception Screening 90 day final study drug administration . Male subject must donate sperm start Screening 90 day final study drug administration . The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history either Short Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) . The subject positive result hepatitis B surface antigen , hepatitis C antibodies Screening know positive human immunodeficiency virus . The subject know suspect allergy component trial product azole class compound , history multiple and/or severe allergy drug food , history severe anaphylactic reaction . The subject smoker ( use tobacco nicotine containing product ) last 6 month . The subject treatment prescribe nonprescribed drug 2 week prior Day 1 , exception occasional use acetaminophen 2 g/day . The subject participate interventional clinical study receive investigational drug within 30 day 5 halflives , whichever longer , prior Screening . The subject participate prior study isavuconazole . The subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen subject test positive screen Day 1 alcohol drug abuse . The subject employee Astellas Group vendor involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>BAL8557</keyword>
	<keyword>BAL4815</keyword>
	<keyword>metformin</keyword>
</DOC>